Alta Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Alta Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-800	Closed	-$92.6K	–	395
2023 Q3	$92.6K	Buy	+800	New	+$86K	0.05%	252

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Alta Advisers's HZNP Position: Q4 2023 in Review

Alta Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 800 shares — an estimated $92.6K sold.

Alta Advisers first reported a position in HZNP in Q3 2023 and held it in 1 quarter. The position peaked at $92.6K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Alta Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Alta Advisers sold 800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $92.6K.
Alta Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023 and held it in 1 quarter.
Alta Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $92.6K in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Alta Advisers's 13F filing for Q4 2023, filed 12 Feb 2024.